AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB) have received an average rating of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $45.09.

Several research firms have issued reports on ANAB. Wedbush restated an “outperform” rating and set a $40.00 price objective (down from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $75.00 to $66.00 and set an “overweight” rating on the stock in a report on Tuesday, November 12th. Guggenheim dropped their price objective on AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, December 12th. UBS Group lifted their price objective on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Finally, HC Wainwright downgraded AnaptysBio from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $52.00 to $19.00 in a report on Wednesday, December 11th.

AnaptysBio Stock Performance

AnaptysBio stock opened at $16.65 on Thursday. The stock’s 50 day moving average price is $25.56 and its 200 day moving average price is $29.51. The firm has a market capitalization of $506.64 million, a PE ratio of -2.76 and a beta of -0.11. AnaptysBio has a one year low of $14.20 and a one year high of $41.31.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping the consensus estimate of ($1.72) by $0.58. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. The firm had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. On average, analysts forecast that AnaptysBio will post -6.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Paul F. Lizzul sold 1,500 shares of AnaptysBio stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $38.67, for a total transaction of $58,005.00. Following the sale, the insider now directly owns 15,398 shares in the company, valued at $595,440.66. The trade was a 8.88 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 33.70% of the stock is owned by company insiders.

Institutional Trading of AnaptysBio

Several institutional investors have recently modified their holdings of the company. Frazier Life Sciences Management L.P. boosted its holdings in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock worth $54,270,000 after buying an additional 1,265,891 shares in the last quarter. FMR LLC grew its holdings in shares of AnaptysBio by 15.3% in the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock worth $110,857,000 after acquiring an additional 438,557 shares during the last quarter. Jennison Associates LLC acquired a new position in shares of AnaptysBio in the 3rd quarter worth $8,874,000. Victory Capital Management Inc. grew its holdings in shares of AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after acquiring an additional 206,750 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after acquiring an additional 168,813 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.